Search

1st EHA-Balkan Hematology Day

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.

Read more

EHA collaborates with THD to provide critical aid to hematologists

The Hague (Netherlands), June 23, 2023. The European Hematology Association (EHA) is proud to announce its partnership with the Türk Hematoloji Derneği (THD) in a joint effort to support hematologists working in earthquake-affected areas in Türkiye and Syria.

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

SWG Educational Activities

MeetingsSession on thrombocytopenias and platelet function disordersAt the EHA 2023 Congress, we held a session on ‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia.

Read more

How to apply for CBTH

TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.

Read more

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Read more

In Memoriam Professor Emeritus Michel Symann

Dear Colleagues,

My dear friend Professor Emeritus Michel Symann passed away on April 23, 2023 at the age of 81.

Read more

Granulocytes & Constitutional Marrow Failures Disorders

The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more